These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23604105)

  • 1. Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells.
    King BC; Hamblin AD; Savage PM; Douglas LR; Hansen TH; French RR; Johnson PW; Glennie MJ
    Cancer Immunol Immunother; 2013 Jun; 62(6):1093-105. PubMed ID: 23604105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.
    Donda A; Cesson V; Mach JP; Corradin G; Primus FJ; Robert B
    Cancer Immun; 2003 Aug; 3():11. PubMed ID: 12916958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
    Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
    Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity thresholds for naive CD8+ CTL activation by peptides and engineered influenza A viruses.
    Denton AE; Wesselingh R; Gras S; Guillonneau C; Olson MR; Mintern JD; Zeng W; Jackson DC; Rossjohn J; Hodgkin PD; Doherty PC; Turner SJ
    J Immunol; 2011 Dec; 187(11):5733-44. PubMed ID: 22039305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes.
    Robert B; Guillaume P; Luescher I; Romero P; Mach JP
    Eur J Immunol; 2000 Nov; 30(11):3165-70. PubMed ID: 11093131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody.
    Oshimi K; Seto T; Oshimi Y; Masuda M; Okumura K; Mizoguchi H
    Blood; 1991 Mar; 77(5):1044-9. PubMed ID: 1825287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.
    Heijnen IA; Glennie MJ; van de Winkel JG
    Cancer Immunol Immunother; 1997; 45(3-4):166-70. PubMed ID: 9435865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity.
    Kreutz M; Giquel B; Hu Q; Abuknesha R; Uematsu S; Akira S; Nestle FO; Diebold SS
    PLoS One; 2012; 7(7):e40208. PubMed ID: 22808118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
    Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
    BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
    Smith EJ; Olson K; Haber LJ; Varghese B; Duramad P; Tustian AD; Oyejide A; Kirshner JR; Canova L; Menon J; Principio J; MacDonald D; Kantrowitz J; Papadopoulos N; Stahl N; Yancopoulos GD; Thurston G; Davis S
    Sci Rep; 2015 Dec; 5():17943. PubMed ID: 26659273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
    Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T-cells specific for natural IgE peptides downregulate IgE production.
    Chen SS; Gong J; Yang YM; Oettgen H; Zanetti M
    Cell Immunol; 2005 Jan; 233(1):11-22. PubMed ID: 15913585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
    Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
    Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on the construction and expression of the human 4-1BBL extracellular domain/anti-CD20 Fab' fusion protein].
    Jiang W; Xiong D; Liu F; Guo H; Su Y; Lü J; Yang C
    Sheng Wu Gong Cheng Xue Bao; 2008 Mar; 24(3):376-80. PubMed ID: 18589811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
    Thibault C; Nelson H; Chapoval AI
    Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.